Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SBT101
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SBT101 is the first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy (AMN). SBT101 was also shown to be well-tolerated in non-human primates through six months post-treatment.
Brand Name : SBT101
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 04, 2023
Lead Product(s) : SBT101
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SBT101
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adrenomyeloneuropathy
Details : SBT101 is the first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy. In preclinical studies, SBT101 demonstrated dose-dependent improvement of disease markers and functional improvement in AM...
Brand Name : SBT101
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 15, 2022
Lead Product(s) : SBT101
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Neurology
Study Phase : Discovery
Recipient : Purespring Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, SwanBio will license the FunSel screening platform from Purespring to explore new targets for early-stage pipeline programs. SwanBio will have an option to develop any targets identified and to own and commercialise any ...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 18, 2022
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Neurology
Highest Development Status : Discovery
Recipient : Purespring Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : SBT101
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SBT101 is first clinical-stage adeno-associated virus (AAV)-based gene therapy candidate for people with adrenomyeloneuropathy (AMN). SBT101 was designed to compensate for the disease-causing ABCD1 mutation.
Brand Name : SBT101
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 27, 2022
Lead Product(s) : SBT101
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SBT101
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Syncona Limited
Deal Size : $56.0 million
Deal Type : Series B Financing
Details : SwanBio’s latest round of financing will support the ongoing evolution into a fully integrated research and development organization, with an initial focus on the clinical advancement of SBT101, including plans to dose patients in a Phase 1/2 trial.
Brand Name : SBT101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 18, 2022
Lead Product(s) : SBT101
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Syncona Limited
Deal Size : $56.0 million
Deal Type : Series B Financing
Lead Product(s) : SBT101
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In all mouse model and NHP studies, IT administration of SBT101 was well tolerated at doses predicted to be clinically relevant in people with AMN, and no drug-associated adverse events were noted.
Brand Name : SBT101
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 17, 2022
Lead Product(s) : SBT101
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?